Team L&M
Bharat Serums and Vaccines (BSV), a leading biopharmaceutical company, opened a world class R&D centre at Airoli, Maharashtra. The centre was inaugurated by Maharashtra’s Health Minister Rajesh Tope. The R&D centre will endeavor to bring scientifically advanced biological, biotechnology products and novel drug delivery systems that deliver better patient outcomes in Women’s Health, Assisted Reproductive Technology and Critical Care & Emergency Medicines.
Speaking on the occasion, Tope said, “Maharashtra is focused at driving scientific research and innovation that aims to address the healthcare needs of our people. We are proud of our home-grown biotechnology leaders like BSV who have been innovating in Maharashtra for over 50 years and bringing many firsts to India in the biological and biotech product segments. The collaboration demonstrated by BSV during the pandemic, with the manufacturing of Liposomal Amphotericin B, has helped in saving lives and managing the pandemic. It is also encouraging to hear of BSV’s ongoing Covid19 Antibody development that will prepare us to fight the future Covid waves, as we continue to meet the unmet healthcare needs of our people.
He added, “With a renewed focus on strengthening women’s health in Maharashtra, we are proud of BSV’s first in the world Anti-Rho (D) immunoglobulin product that has assisted in safe deliveries and in bringing good health to Rh-negative mothers and new-borns in our state. Looking forward, we would like to build a patient-centred, innovation-driven, robust healthcare ecosystem in Maharashtra where companies such as BSV will be able to innovate and bring scientifically advanced products to India and the world.”
“Our scientists at the R&D centre continue to demonstrate our commitment towards Aatmanirbhar Bharat, as we innovate in Maharashtra for India and the world. BSV’s Anti-Rho (D) immunoglobulin product is the world’s first marketed recombinant Anti-D with patents in India, US, Europe, Australia and Canada,” said Sanjiv Navangul, Managing Director & CEO, BSV.
“Maharashtra accounts for 1,00,000 Rh-negative pregnant mothers annually, of which, 40,000 have benefited from BSV’s Anti-Rho (D) immunoglobulin product. Going ahead we are hopeful that we will be able to bridge the gap and partner with the Maharashtra Government to expand access and serve more needy Rh-negative mothers across our state.
